From launching a new product to adjusting existing price structures, it’s critical that pharmaceutical manufacturers are aware of how their pricing decisions can trigger state-level reporting obligations across the US.

However, with more than 30 unique reporting requirements already enacted and more pending legislation on the way, it can be a daunting challenge to stay up-to-date on what information is required to be reported, where to submit reports, and when reports are due for a given drug pricing situation. Plus, keeping track of the increased implementation of Prescription Drug Affordability Boards by state, with varying levels of authority.

In this webinar, our presenters break down the current state drug price reporting landscape, including key report types and requirements, and how manufacturers can navigate these regulations with ease to quickly identify what’s applicable in light of their current and future drug pricing models.

Checkout a preview here:

Would you like a deep dive review of our State Drug Price Reporting module in RegulatoryID?

Similar Posts